Just three of the drugs on the list of 10 products selected for Medicare price negotiation are not currently rebated at levels that exceed the minimum discounts established by the Inflation Reduction Act, which means they offer the best potential for savings, according to a recent analysis by drug pricing data and analytics firm SSR Health.
The drugs are AbbVie Inc./Johnson & Johnson’s Imbruvica for cancer and the anti-inflammatories Enbrel (Amgen, Inc.) and...







